Long-term management of gastroesophageal reflux disease and its complications

American Journal of Gastroenterology

Volumn 92, Issue 4, 1997, Pages

  Richter, Joel E ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; OMEPRAZOLE; PROKINETIC AGENT; PROTON PUMP INHIBITOR;

ARTICLE; BARRETT ESOPHAGUS; COST EFFECTIVENESS ANALYSIS; DRUG EFFECT; GASTROESOPHAGEAL REFLUX; HUMAN; PRIORITY JOURNAL; RELAPSE; STOMACH ACID SECRETION;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ANTACIDS; ANTI-ULCER AGENTS; GASTROESOPHAGEAL REFLUX; HISTAMINE H2 ANTAGONISTS; HUMANS; LIFE STYLE; OMEPRAZOLE; PROTON PUMPS; TIME FACTORS;

EID: 0030985129     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Spechler SJ. Epidemiology and natural history of gastro-oesophageal reflux disease. Digestion 1992;51:24-9.
2. Bell NJV, Burget D, Howden CW, et al. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 1992;51(suppl 1):59-67.
3. DeVault KR, Castell DO. Current diagnosis and treatment of gastroesophageal reflux disease. Mayo Clin Proc 1994;69:867-76.
4. Dobrilla G, DiFede F. Treatment of gastroesophageal (acid) reflux with lansoprazole: An overview. Clin Therap 1993;15(suppl B):2-13.
5. Sivri B, McCallum RW. What has the surgeon to know about pathophysiology of reflux disease? World J Surg 1992;16:294-9.
6. Ireland AC, Holloway RH, Toouli J, et al. Mechanisms underlying the anti-reflux action of fundoplication. Gut 1993;34:303-8.
7. Spechler SJ, and the Department of Veterans Affairs Gastroesophageal Reflux Disease Study Group. A comparison of medical and surgical therapy for complicated gastroesophageal reflux disease in veterans. N Engl J Med 1992;326:786-92.
8. Lundell LR. The knife or the pill in the long-term treatment of gastroesophageal reflux disease? Yale J Biol Med 1994;67:233-46.
9. Roberts PJ, Cuschieri A. Laparoscopic and thoracoscopic antireflux surgery. Ann Chir Gynaecol 1995;84:130-7.
10. Tytgat GNJ, Anker Hansen OJ, Carling L, et al. Effect of cisapride on relapse of reflux oesophagitis, healed with an antisecretory drug. Scand J Gastroenterol 1992;27:175-83.
11. Lieberman DA. Medical therapy for chronic reflux esophagitis: Long-term follow-up. Arch Intern Med 1987;147:1717-20.
12. Tytgat GNJ, Nio CY, Schotborgh RH. Reflux esophagitis. Scand J Gastroenterol 1990;25(suppl 175):1-12.
13. Blum AL, Adami B, Bouzo MH, et al. Effect of cisapride on relapse of esophagitis: A multinational, placebo-controlled trial in patients healed with an antisecretory drug. Dig Dis Sci 1993;38:551-60.
14. Toussaint J, Gossuin A, Deruyttere M, et al. Healing and prevention of relapse of reflux oesophagitis by cisapride. Gut 1991;32:1280-5.
15. Howden CW, Castell DO, Cohen S, et al. The rationale for continuous maintenance treatment of reflux esophagitis. Arch Intern Med 1995; 155:1465-71.
16. Klinkenberg-Knol EC. The role of omeprazole in healing and prevention of reflux disease. Hepatogastroenterology 1992;39(suppl I):27-30.
17. Bardhan KD. Is there any acid peptic disease that is refractory to proton pump inhibitors? Aliment Pharmacol Ther 1993;7(suppl 1):13-24.
18. 2-receptor antagonist tolerance and gastroesophageal reflux disease: A comparison of nizatidine, ranitidine, and famotidine on esophageal and gastric pH over 28 days of standard therapy. Am J Gastroenterol 1993;88:1487.
19. Dent J, Yeomans ND, Mackinnon M, et al. Omeprazole v ranitidine for prevention of relapse in reflux oesophagitis: A controlled double-blind trial of their efficacy and safety. Gut 1994;35:590-8.
20. Sandmark S, Carlsson R, Fausa O, et al. Omeprazole or ranitidine in the treatment of reflux esophagitis. Scand J Gastroenterol 1988;23: 625-32.
21. Gough AL, Long RG, Cooper BT, et al. Lansoprazole versus ranitidine in the maintenance treatment of reflux oesophagitis. Aliment Pharmacol Ther 1996;10:529-39.
22. Hetzel DJ. Controlled clinical trials of omeprazole in the long-term management of reflux disease. Digestion 1992;51(suppl 1):35-42.
23. Spencer CM, Faulds D. Lansoprazole: A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders. Drugs 1994;48:404-30.
24. Robinson M, Lanza F, Avner D, et al. Effective maintenance treatment of reflux esophagitis with low-dose lansoprazole: A randomized double-blind, placebo-controlled trial. Ann Intern Med 1996;124:859-67.
25. Sontag SJ, Kogut DG, Fleischmann R, et al. Lansoprazole prevents recurrence of erosive reflux esophagitis previously resistant to H2-RA therapy. Am J Gastroenterol 1996;91:1758-65.
26. Klinkenberg-Knol EC, Festen HPM, Jansen JBMJ, et al. Long-term treatment with omeprazole for refractory reflux esophagitis: Efficacy and safety. Ann Intern Med 1994;121:161-7.
27. Koop H, Arnold R. Long-term maintenance treatment of reflux esophagitis with omeprazole: Prospective study in patients with H2-blocker-resistant esophagitis. Dig Dis Sci 1991;36:552-7.
28. +-ATPase inhibitor: A controlled, double-blind study. Am J Gastroenterol 1993;88:1212-7.
29. Marks RD, Richter JE, Rizzo J, et al. Omeprazole versus H2-receptor antagonists in treating patients with peptic stricture and esophagitis. Gastroenterology 1994;106:907-15.
30. Swarbrick ET, Gough AL, Christian J, et al. Prevention of recurrence of oesophageal stricture: A comparative study of lansoprazole and high dose ranitidine. Gastroenterology 1994;106:A189.
31. Sampliner RE. Effect of up to 3 years of high-dose lansoprazole on Barren's esophagus. Am J Gastroenterol 1994;89:1844-8.
32. Wang KK. Barrett's esophagus: Current and future management. Compr Ther 1994;20:36-43.
33. Attwood SE. Barrett's esophagus. Curr Opin Gen Surg 1993;180-8.
34. Berstein IT, Kruse P, Andersen IB. Barrett's oesophagus. Dig Dis 1994;12:98-105.
35. Falk GW. Barrett's esophagus. Gastrointest Endosc Clin North Am 1994;4:773-89.